CA Patent

CA2752020A1 — Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome

Assigned to Cedars Sinai Medical Center · Expires 2010-08-19 · 16y expired

What this patent protects

The present invention provides for methods of preventing IBS, preventing long term irregular bowel pattern, reducing the likelihood of developing or having IBS, reducing the likelihood of developing or having long term irregular bowel pattern, mitigating IBS, mitigating long term…

USPTO Abstract

The present invention provides for methods of preventing IBS, preventing long term irregular bowel pattern, reducing the likelihood of developing or having IBS, reducing the likelihood of developing or having long term irregular bowel pattern, mitigating IBS, mitigating long term irregular bowel pattern and reducing the likelihood of developing non-ulcer dyspepsia. The methods comprise providing an antibiotic and administering the antibiotic to a subject in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA2752020A1
Jurisdiction
CA
Classification
—
Expires
2010-08-19
Drug substance claim
No
Drug product claim
No
Assignee
Cedars Sinai Medical Center
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.